Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS3-007a for Diagnosis of AGHD
NCT07259564Phase 2Terminated
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GS3-007 in adult growth hormone deficiency (AGHD), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started Dec 2025; status: terminated.
02
Drugs
GS3-007
03
Conditions
adult growth hormone deficiency (AGHD)
Beyond the preview
Go deeper on NCT07259564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07259564.